What is AtriCure's market cap?

AtriCure (ATRC) has a market capitalization of $1.9B and trades on NASDAQ.

What is AtriCure's revenue and profitability?

AtriCure generated $569.6M in trailing twelve-month revenue with net income of $2.6M, representing a net margin of -5.6%. Gross margin stands at 76.3%, with free cash flow of $53.1M. These figures are based on the Q2 2026 filing.

Who are AtriCure's competitors?

AtriCure's key competitors include Boston Scientific, Medtronic, Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Where is AtriCure headquartered?

AtriCure is headquartered in United States of America and employs approximately 1,200 people. It has been publicly traded since 2005.

AtriCure

ATRC

AtriCure is a medical technology company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain.

Market cap

$1.89B+8.8%

Revenue$569.6M+13.9%

Net income$2.6M+107%

Free cash flow$53.1M+456%

EPS (diluted)$0.04+105%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 23, 2026

Revenue$153.6MBeat by $1.8M EPS$0.18Beat by $0.18

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$153.6M+12.8%

Gross profit$118.6M+16.9%

Operating income$9.7M+256%

Net income$9.0M+245%

EPS (diluted)$0.18+238%

Balance sheet

See full

Cash & equivalents$167.8M+42.4%

Total debt$75.5M-3.8%

Total equity$516.4M+11.2%

Total assets$676.6M+11.1%

Cash flow

See full

Operating cash flow$22.2M+2.7%

CapEx$3.8M+41.5%

Free cash flow$18.4M-2.8%

Valuation & ratios

Valuation

See full

Market cap$1.89B+8.8%

Enterprise value$1.8B+12.1%

P/E726.2×—

P/S3.3×0.0×

Profitability

See full

Gross margin76.3%+1.6pp

FCF margin9.3%—

Returns & leverage

See full

Debt / equity0.1×0.0×

Current ratio4.2×+0.3×

Segments

By geography

See full

Total International$28.0M+9.6%

Europe$17.2M+6.7%

Asia Pacific$8.6M+15.4%

Other International$2.2M+12.1%

By product

See full

Appendage management$64.0M+14.4%

Open ablation$52.1M+11.3%

Pain management$29.4M+26.9%

Minimally invasive ablation$8.1M-21.2%

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

Boston Scientific$67.6B-56.8%

Pulse Biosciences, Inc.$2.3B+122%

AtriCure$1.9B+15.1%

Adagio Medical$10.7M-57.1%

Catheter Precision$1.0M-61.7%

By revenue growth

AtriCure+13.9%

Boston Scientific+13.5%

Medtronic+8.4%

Abbott+8.1%

Johnson & Johnson+8.1%

By net margin

Johnson & Johnson21.48%-3.5pp

Boston Scientific17.48%+4.0pp

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

AtriCure-5.55%+8.1pp

Pulse Biosciences, Inc.-9,929.03%—

Profile

AtriCure is a medical technology company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain. The company provides innovative cardiac ablation and exclusion devices that enable surgeons to perform faster, less invasive procedures with clinically proven outcomes. Its value proposition centers on reducing stroke risk and managing chronic pain through advanced radio frequency and cryogenic energy platforms.

Competitive position

AtriCure is a market leader in surgical Afib treatment and a pioneer in Cryo Nerve Block therapy for post-operative pain.

GeographiesUnited States, Germany, France, United Kingdom, Benelux, Australia, Canada

Customer segmentsHospitals, Specialized Medical Centers, Surgical Clinics

Business modelDirect Sales, Razor-and-blade, Distributor-led

SuppliersElectronic component manufacturers, Medical-grade plastic and metal suppliers, Specialized energy generator manufacturers

CustomersAcute care hospitals, Cardiac surgery centers, International medical distributors

CountryUnited States of America

Listed2005

Employees1.2K

CEOMichael H. Carrel

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websiteatricure.com

FilingsSEC EDGAR

Ask your AI about AtriCure.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AtriCure's market cap?: AtriCure (ATRC) has a market capitalization of $1.9B and trades on NASDAQ.
What is AtriCure's revenue and profitability?: AtriCure generated $569.6M in trailing twelve-month revenue with net income of $2.6M, representing a net margin of -5.6%. Gross margin stands at 76.3%, with free cash flow of $53.1M. These figures are based on the Q2 2026 filing.
Who are AtriCure's competitors?: AtriCure's key competitors include Boston Scientific, Medtronic, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Where is AtriCure headquartered?: AtriCure is headquartered in United States of America and employs approximately 1,200 people. It has been publicly traded since 2005.